Activated PI3K and RTK signaling and response/resistance to HER2 targeted therapy

被引：0
|
作者：
O'Brien, Neil
Browne, Brigid
Chow, Lucy
Ginther, Charles
Bensadigh, Brian
Atefi, Mohammad
Arboleda, Jane
Duffy, Michael
Crown, John
O'Donovan, Norma
Slamon, Dennis
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Natl Inst Cellular Biotechnol, Dublin, Ireland
[3] Conway Inst, UCD Sch Med & Med Sci, Dublin, Ireland
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
765
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.
    O'Brien, N. A.
    Browne, B. C.
    Chow, L.
    Ginther, C.
    Bensadigh, B.
    Arboleda, J.
    Duffy, M. J.
    Crown, J.
    O'Donovan, N.
    Slamon, D. J.
    CANCER RESEARCH, 2009, 69 (02) : 160S - 160S
  • [2] The Role of the PI3K/AKT, RAS/MAPK and Novel Signaling Pathways in Resistance to HER2-Targeted Therapy
    O'Brien, N. A.
    Wilcox, K.
    McDermott, M.
    Crown, J.
    O'Donovan, N.
    Slamon, D. J.
    CANCER RESEARCH, 2010, 70
  • [3] HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3
    Ruiz-Saenz, Ana
    Dreyer, Courtney
    Campbell, Marcia R.
    Steri, Veronica
    Gulizia, Nate
    Moasser, Mark M.
    CANCER RESEARCH, 2018, 78 (13) : 3645 - 3658
  • [4] Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy
    Saintigny, Pierre
    Mitani, Yoshitsugu
    Pytynia, Kristen B.
    Ferrarotto, Renata
    Roberts, Dianna B.
    Weber, Randal S.
    Kies, Merrill S.
    Maity, Sankar N.
    Lin, Sue-Hwa
    El-Naggar, Adel K.
    CANCER, 2018, 124 (18) : 3693 - 3705
  • [5] Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
    Hanker, Ariella B.
    Estrada, Monica Valeria
    Bianchini, Giampaolo
    Moore, Preston D.
    Zhao, Junfei
    Cheng, Feixiong
    Koch, James P.
    Gianni, Luca
    Tyson, Darren R.
    Sanchez, Violeta
    Rexer, Brent N.
    Sanders, Melinda E.
    Zhao, Zhongming
    Stricker, Thomas P.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2017, 77 (12) : 3280 - 3292
  • [6] HER2 targeted therapy: Determinants of response and mechanisms of resistance
    Schiff, R.
    Veeraraghavan, J.
    De Angelis, C.
    Osborne, C.
    Rimawi, M. F.
    CANCER RESEARCH, 2021, 81 (04)
  • [7] A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    Rodrik-Outmezguine, V.
    Scaltriti, M. Maurizio
    Sakr, R.
    Will, M.
    Giri, D.
    Hudis, C.
    Baselga, J.
    King, T.
    Rosen, N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 127 - 127
  • [8] Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
    Poovassery, Jayakumar S.
    Kang, Jeffrey C.
    Kim, Dongyoung
    Ober, Raimund J.
    Ward, E. Sally
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 267 - 277
  • [9] PI3K pathway as a major determinant of resistance to HER2-targeted therapy in advanced gastric cancer
    Kim, Hyo Song
    Zhang, Xianglan
    Park, Kyu Hyun
    Park, Ji Soo
    Kim, Ki Hyang
    Chung, Hyun Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Targeting HER2 and PI3K in Uterine Serous Cancer
    Diver, E. J.
    Hernandez, S. F.
    Scaltriti, M.
    Rueda, B. R.
    Growdon, W. B.
    GYNECOLOGIC ONCOLOGY, 2015, 139 (03) : 596 - 596
12345